

Cite this: *Chem. Sci.*, 2024, 15, 17927

All publication charges for this article have been paid for by the Royal Society of Chemistry

Charting the coordinative landscape of the ^{18}F – $\text{Sc}/^{44}\text{Sc}/^{177}\text{Lu}$ triad with the tri-aza-cyclononane (tacn) scaffold†

Cormac A. A. Kelderman,^{ab} Owen M. Glaser,^{ab} Jennifer N. Whetter,^{ab} Eduardo Aluicio-Sarduy,^c Jason C. Mixdorf,^c Kyana M. Sanders,^{ib} Ilia A. Guzei,^b Todd E. Barnhart,^c Jonathan W. Engle^c and Eszter Boros^{ib*ab}

The widely established PET isotope ^{18}F does not have a therapeutic partner. We have recently established that the Sc–F bond can be formed under aqueous, high yielding conditions, paving the way to providing ^{18}F as diagnostic partners to ^{47}Sc and ^{177}Lu radiotherapeutics. Here, we synthesized a library of tacn-based chelators comprised of 10 structurally unique permutations incorporating acetate, methyl-benzamide and picolinate donor arms. The chelator library encompasses chelators ranging from 6- to 9-dentate, and produces complex changes ranging from +3 to –1. The corresponding Sc–F/Sc and Lu chelate complexes were characterized using computational, spectroscopic and potentiometric methods, followed by optimization of radiolabeling with ^{18}F , ^{44}Sc and ^{177}Lu and concluded by *in vivo* validation. We identify characterization benchmarks that chart the coordinative landscape of radiochelation approaches for this unusual triad. Our screening identifies two ligand systems, H_2L^{111} and H_3L^{201} as ideal, readily functionalizable constructs for prospective, targeted theranostic applications with $^{18}\text{F}/^{44}\text{Sc}/^{177}\text{Lu}$.

Received 16th July 2024
Accepted 27th September 2024

DOI: 10.1039/d4sc04735d

rsc.li/chemical-science

Introduction

The short-lived isotope ^{18}F ($E_{\beta_{\text{avg}}^+} = 250$ keV, $t_{1/2} = 109$ min) is currently the most frequently and readily utilized positron emission tomography (PET) isotope worldwide, for both diagnostic and research studies, frequently preceding administration of therapeutic isotopes for the management of disease with radiotherapy.¹ The lack of a suitable therapeutic isotopologue for ^{18}F , can render ^{18}F PET probes suboptimal diagnostic partners to chemically dissimilar, radiometal-based radiotherapies.² Additionally, conventional radiofluorination strategies involve C–F bond formation in anhydrous, aprotic solvents at high temperatures, which can limit the radiolabeling of thermally and chemically sensitive (bio)molecules.³ To address this issue, the use of prosthetic groups⁴ and the formation of B–F, Si–F and Al–F bonds has been successfully explored to access mild radiochemical ^{18}F labeling strategies compatible with aqueous solvents and proteins.^{5–8}

However, none of these approaches provide access to a chemically identical theranostic pair, where the same chemical construct can be employed to incorporate ^{18}F and a radiometal such as the widely commercially successful radiotherapeutic isotope ^{177}Lu ($E_{\beta_{\text{avg}}^-} = 134$ keV, $t_{1/2} = 159.6$ h), or the more experimental Sc-triad: ^{43}Sc ($E_{\beta_{\text{avg}}^+} = 476$ keV, $t_{1/2} = 3.9$ h), ^{44}Sc ($E_{\beta_{\text{avg}}^+} = 632$ keV, $t_{1/2} = 4$ h) or ^{47}Sc ($E_{\beta_{\text{avg}}^-} = 162$ keV, $t_{1/2} = 80.4$ h).^{9–12} Establishing such a theranostic triad or tetrad could take advantage of the growing, global low energy cyclotron infrastructure and provide accelerated development and translation of theranostic agents. Previously, we established that the displacement of a labile, inner-sphere water of the 7-coordinate Sc(mpatcn) (herein listed as $[\text{ScF}(\text{L}^{201})]^-$) and Sc(picaga) chelate with a $^{18}\text{F}^-$ ion produces *in vivo* compatible and ^{18}F – $\text{Sc}/^{47}\text{Sc}(\text{picaga})$ -conjugates that show no statistical difference with respect to their *in vivo* biodistribution.¹³

However, questions and challenges remained after our pilot study: (1) what are the relevant characteristics of chelators that can stabilize Sc–F, Sc and Lu chelates under macroscopic and radiotracer level conditions? Can we establish benchmarks using analytical characterization methods to predict compatibility with the theranostic F/Sc/Lu triad? (2) Can we uncover coordination complexes that improve access to bifunctional constructs by simplifying synthesis? (3) Can we improve radiochemical labeling approaches to increase compatibility with currently employed radiopharmaceutical practices and accelerate clinical translation (Fig. 1)?

^aDepartment of Chemistry, Stony Brook University, Stony Brook, New York 11790, USA. E-mail: eboros@wisc.edu

^bDepartment of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA

^cDepartment of Medical Physics, University of Wisconsin-Madison, Wisconsin 53705, USA

† Electronic supplementary information (ESI) available. CCDC 2369298. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d4sc04735d>






Fig. 1 Overview of desired reactivity with optimized tacn ligand scaffold to enable chelation of radioisotopes of Sc^{3+} , Lu^{3+} and the $[\text{Sc-F}]^{2+}$ core. Reactions are indicated as equilibria with favored product/reactivity indicated.

Here, we address these questions by probing a series of triaza-cyclononane (tacn) based chelators. The compound library, a permutation of acetate, methyl-benzylamide and picolinate donor arms, is synthetically accessible by sequential alkylations. Following characterization, a combination of computational, multi-nuclear spectroscopic, spectrophotometric, and radiochemical methods was employed to predict and identify the formation of *in vivo* compatible radiochemical coordination complexes. The subsequent *in vivo* analysis identified optimal chelator denticity and charge equilibration properties that will enable simplified, targeted imaging and therapy approaches with a single bifunctional chelator using ^{18}F , ^{44}Sc and ^{177}Lu isotopes.

Results and discussion

Ligand design and chemical synthesis

Our previous work showed that the 7-coordinate ligand mpatcn formed complexes with all three isotopes of interest, with the bifunctional analogue picaga exhibiting good *in vivo* performance for targeted imaging and therapy applications. However, we did not systematically explore how the ligand denticity, donor group basicity and resultant charge would affect the corresponding chelator's ability to stabilize all three types of

complexes. In accordance with previous work by us and others, preferred ligand systems for Sc^{3+} and Lu^{3+} overwhelmingly incorporate hard to borderline hard donors such as aliphatic amines, acetates and picolinate donors. To access a diverse (not exhaustive) chelator library with respect to hardness and denticity, we selected acetate, methyl-benzylamide and picolinate donor arms and employed sequential alkylation with the corresponding, acetate protected alkyl bromide species (ESI, Schemes S1 and S2†). While acetate and picolinate donor groups exhibit only one coordinative mode, amide donors can coordinate by carbonyl-O or deprotonated amido-N, especially in presence of Lewis acidic metal ions such as Sc^{3+} . To avoid coordinative ambiguity, we incorporate methyl-benzylamide which enforces coordination through the carbonyl-O exclusively.

Chromatographic separation following deprotection of the acetate donor groups of the acetyl and picolyl groups affords the free chelators which can be directly employed to form the coordination complex species of interest. 10 permutations are possible if all positions are alkylated (Fig. 2A, Table 1). Of these, four are 6-coordinate, three are 7-coordinate, two are 8-coordinate and one is 9-coordinate. Previous literature on aqueous Sc chelation indicates a pronounced preference for the formation of 8-coordinate complex species in aqueous environments, with 6- and 7-coordinate complexes forming ternary complexes with solvent or buffer molecules.¹⁴ 9-coordinate Sc-coordination complexes are rare, indicating that the 8- and 9-coordinate ligand systems will not accommodate the coordination of a ternary F^- ligand. All non-radioactive complexes were formed from $\text{MCl}_3 \cdot 6\text{H}_2\text{O}$ ($\text{M} = \text{Sc}^{3+}$ or Lu^{3+}) in presence of ammonium acetate buffer to mimic radiochemical labelling conditions and keep the solution pH optimal for complexation. Subsequent fluorination to produce the Sc-F complex was achieved by treatment of the corresponding Sc-complexes $[\text{Sc}(\text{L}^{201})]$, $[\text{Sc}(\text{L}^{111})]^+$, and $[\text{Sc}(\text{L}^{021})]^{2+}$ with 5 equivalents of NH_4F or CsF , followed by precipitation of excess fluoride *via* redissolution of the soluble Sc-F complex in acetonitrile to remove insoluble, residual fluoride salts. Of note, while mass spectrometric evidence of the formation of the ScF complex of 6-coordinate




Fig. 2 (A) general ligand design scheme incorporating acetate, methyl-benzylamide and picolinate donor arms in different permutations to produce 10 ligand systems discussed herein. The ligand nomenclature system is designed so that the three digits represent the number of acetyl, amido, and picolyl groups, respectively. Numbering for 9 of the ligands is shown around the wheel with the 10th ligand, L^{111} , being depicted in the center. (B) Selected 6- and 7-coordinate chelator structures with corresponding color-coded donor arms and representative nomenclature.



Table 1 Summary of naming convention, Sc/Lu complex charges (m), ScF complex charges (n) and ligand coordination number (CN) of all synthesized ligand systems of the permutational tacn library described in this work

Ligand (H_nL^{xxx})	H_3L^{300}	H_2L^{210}	HL^{120}	L^{030}	H_3L^{201}	H_2L^{111}	HL^{021}	HL^{102}	H_2L^{012}	H_2L^{003}
$[M(L^{xxx})]^m$	0	+1	+2	+3	0	+1	+2	0	+1	0
$[ScF(L^{xxx})]^n$	-1	0	+1	+2	-1	0	+1	-1	0	-1
Ligand CN	6	6	6	6	7	7	7	8	8	9

ligand systems was obtained, no significant amounts of product could be isolated. Absence of the 6-coordinate Sc complexes coincided with appearance of precipitate in the reaction mixture attributed to formation of insoluble ScF_3 .

Solid state characterization

Crystallization attempts were only successful with $[Sc(L^{003})] \cdot 3H_2O$ (CCDC: 2369298, Fig. 3, ESI Tables S12–S20†). The Sc atom is at the core of a 9-coordinate tricapped trigonal prismatic complex isostructural with several Ln analogues (Ln = Nd, Eu, Gd, Tb, Yb, and Lu) reported in the literature.^{15–17} The coordination environments of high denticity Sc^{3+} and lanthanide atoms in these complexes are similar despite differences in the ionic radii of these metals ($Sc^{3+} = 0.745 \text{ \AA}$, $Ln^{3+} = 0.861–1.032 \text{ \AA}$). The structural similarity between Sc^{3+} and Lu^{3+} complexes is noteworthy due to the clinical use of ^{177}Lu for targeted radiation therapy. As expected, the metal–ligand bond distances for this series of complexes exhibit a positive correlation with the ionic radii of the metal center (*i.e.* longer metal–ligand distances correspond to metals with larger ionic radii) when comparing structures determined at the same data collection temperature (Table 2).

Spectroscopic solution phase characterization

Additionally, the complexes were characterized using 1H , ^{13}C $\{^1H\}$, ^{45}Sc and ^{19}F NMR spectroscopy. While 1H and $^{13}C\{^1H\}$

Table 2 Metal-to-ligand donor bond distances, ligand donor interplane distances, tacn macrocycle torsion angles and interplane torsion angles (dihedral angles)

	$Sc(L^{003})-\Delta(\lambda,\lambda,\lambda)$	$Lu(L^{003})-\Delta(\lambda,\lambda,\lambda)$	Difference
Mean bond distances [\AA]			
M– N_{tacn}	2.564	2.613	+0.049
M– N_{py}	2.426	2.494	+0.068
M–O	2.206	2.309	+0.103
Mean plane distances [\AA]			
N_{tacn} – N_{py}	2.014	2.068	+0.054
N_{tacn} –O	3.401	3.490	+0.089
N_{py} –O	1.387	1.423	+0.036
N_{tacn} –M	1.960	2.006	+0.046
Mean torsion [$^\circ$]			
N_{tacn} – N_{tacn}	-45.95	-46.22	-0.27
N_{tacn} – N_{py}	43.70	42.06	-1.64
N_{tacn} –O	103.83	100.39	-3.44
N_{py} –O	60.15	58.37	-1.78

spectra were characteristic of the asymmetric and dynamic aza-macrocycle solution environment, ^{45}Sc and ^{19}F spectral data provided clearer insight into solution chemical features of the corresponding complexes.¹⁸ Acquisition of spectral data in MeOD limits the formation of ternary Sc complexes with solvent and buffer molecules such as acetate and water. Literature on ^{45}Sc spectral data for aqueous coordination complexes is sparse, as the ^{45}Sc quadrupole produces broad peaks in asymmetric environments and therefore confers little structural information when considered in isolation. However, the compound library described here provides a data set large enough that specific trends emerge (Fig. 4A and B). Specifically, we find that chemical shift regions are characteristic for coordinative numbers and solvent access. While not observed to date for mononuclear, solution-phase systems, this correlates well with ^{45}Sc NMR spectroscopy data collected on solid state structures.^{19–21} In MeOD, Sc complexes producing ^{45}Sc chemical shifts ranging from 65 to 75 ppm are enveloped by a 7-coordinate ligand. Chemical shifts ranging from 95 to 105 ppm are produced when Sc is in a 6-coordinate ligand environment with acetate buffer molecules occupying the inner sphere. Under the same conditions, 8-coordinate ligand systems without inner sphere coordination are found above 125 ppm. Of note, even in MeOD, the 8-coordinate $[Sc(L^{012})]^+$ produces two characteristic signals (127 and 73 ppm respectively), indicative of multiple solution species, with 8-coordinate and a potential 7-coordinate species in dynamic equilibrium. Displacement of the inner-sphere water ligand with F^- to form $[ScF(L^{201})]$, $[ScF(L^{111})]$




Fig. 3 Single crystal X-ray diffraction representation of the $Sc(L^{003})-\Delta(\lambda,\lambda,\lambda)$ complex at 50% thermal ellipsoid probability. Hydrogen atoms and solvent molecules omitted for clarity.






Fig. 4 NMR-spectroscopic characterization of Sc and ScF complex series synthesized as part of this work. (A) ^{45}Sc -NMR spectra of $[\text{ScF}(\text{L}^{111})]$ (top) and $[\text{Sc}(\text{L}^{111})]^+$ (bottom) in D_2O (red trace), and MeOD (black trace). (B) Summary of ^{45}Sc spectral data in MeOD of the entire complex series shows characteristic chemical shift ranges for all complexes investigated, grouped as follows, from highest to lowest field: 9-coordinate symmetric species (triangle), 7-coordinate species (diamonds), 6-coordinate species (spheres) and 8-coordinate species (squares); notably, $[\text{ScF}(\text{L}^{021})]^+$ exhibits two distinct solution species. (C) ^{19}F -NMR spectra of $[\text{ScF}(\text{L}^{021})]^+$, $[\text{ScF}(\text{L}^{111})]$ and $[\text{ScF}(\text{L}^{201})]^-$, indicating increase in electronic shielding as the negative complex charge increases.

and $[\text{ScF}(\text{L}^{021})]^+$ results in an upfield shift of the ^{45}Sc chemical shift of <5 ppm and significant line broadening of the ^{45}Sc resonance. For the Sc-F complexes, ^{19}F NMR provides additional relevant insight. Due to the quadrupolar coupling of the ^{19}F and ^{45}Sc nuclei, corresponding spectral features are broad, but appear in a characteristic range from -9.3 , -3.8 to 2.5 ppm for $[\text{ScF}(\text{L}^{201})]^-$, $[\text{ScF}(\text{L}^{111})]$ and $[\text{ScF}(\text{L}^{021})]^+$, respectively. The chemical shift range is typical for metal-bound F^- species and the observed trend reflects increasing de-shielding of the fluoride ion in accordance with increasing positive charge.²² The formation of coordinative isomers is observed in all spectra, but indeed produces two distinct signals for $[\text{ScF}(\text{L}^{021})]^+$ where isomer interconversion due to presence of the methyl-benzylamide groups is further slowed. Taken together, the heteronuclear spectroscopy data offers unprecedented insight into the coordination environment of these complexes, providing clear delineation of desirable complex hallmarks of 65–75 ppm, characteristic for 7-coordinate ligand systems.

To gain further insight into structural parameters that may be predictive of the formation of stabilized ScF complexes, we conducted DFT structure optimization and determination of the bond dissociation energy (BDE) of $[\text{Sc}(\text{OH}_2)(\text{L}^{\text{xxx}})]$, $[\text{Sc}(\text{OH})(\text{L}^{\text{xxx}})]$ and $[\text{ScF}(\text{L}^{\text{xxx}})]$ complexes where inner-sphere coordination was readily accessible (6- and 7-coordinate complex systems). For all complexes, Δ - and Λ -configurations were calculated at the B3LYP-D3(BJ)/cc-pVDZ level of theory with SMD solvation and considering a single inner sphere ternary ligand (F^- , OH^- or OH_2), Table 3 (further reading and parameters can be found within the Supportive Information, Sections 1.5 and 4). All ligand systems which incorporate the methyl-benzylamido donor were truncated to the bis-methylamide species to decrease isomeric complexity induced by the formation of *E/Z* isomers. In accordance with our previous computational characterization of the $[\text{ScF}(\text{L}^{201})]^-$ complex, all investigated complex systems exhibit BDE values above those obtained for the corresponding hydroxo complex species by 30–50 kJ mol^{-1} , and greater than 200 kJ mol^{-1} above

Table 3 DFT optimized, structural parameters for 6- and 7-coordinate ligand systems investigated, including relevant bond lengths and calculated bond dissociation energies (BDE). Ternary coordination number values refer to the species employed for corresponding DFT calculations

Complex	BDE (kJ mol^{-1})			Calculated bond length [\AA]		
	X=OH ₂	X=OH ⁻	X=F ⁻	Sc-F	Sc-OH ₂	Ternary CN
Δ -ScXL ³⁰⁰	54	219	270	1.967	2.349	7
Λ -ScXL ³⁰⁰	54	218	271	1.967	2.350	7
Δ -ScXL ²¹⁰	60	236	285	1.957	2.334	7
Λ -ScXL ²¹⁰	60	236	285	1.957	2.334	7
Δ -ScXL ¹²⁰	63	250	299	1.952	2.322	7
Λ -ScXL ¹²⁰	60	247	296	1.952	2.324	7
Δ -ScXL ²⁰¹	27	189	229	1.958	2.354	8
Λ -ScXL ²⁰¹	27	189	229	1.958	2.354	8
M- Δ -ScXL ¹¹¹	34	206	250	1.951	2.311	8
M- Λ -ScXL ¹¹¹	34	199	244	1.954	2.337	8
P- Δ -ScXL ¹¹¹	34	199	244	1.954	2.337	8
P- Λ -ScXL ¹¹¹	35	206	251	1.951	2.311	8
Δ -ScXL ⁰²¹	40	219	263	1.949	2.324	8
Λ -ScXL ⁰²¹	39	218	262	1.948	2.324	8

the aqua complex. Within the 6- and 7-coordinate complex series evaluated, a trend emerges with respect to relative Sc-F bond lengths: increasing complex charge results in a shortened Sc-OH₂ and Sc-F bond lengths and increasing BDE values. Computed Sc-OH₂ bond lengths are elongated by 0.1–0.2 \AA when compared with crystal structure data of the few 7-coordinate Sc chelate systems reported, ranging from 2.24 (AAZTA)¹⁴ to 2.12 (py₂macrodiipa)²³ and 2.14 (py-macrodiipa)²⁴ and indicate increased inner sphere crowding in small-cavity macrocycle systems. The same relative trends are observed for Sc-OH₂, albeit restriction of the inner sphere ternary ligand binding pocket may diminish H₂O coordination, while the F^- ternary ligand can be accommodated throughout the entire ligand series due to its smaller relative size at a virtually unchanged



bond length. This behavior correlates well with observations made for the formation of aqua complexes across the lanthanide series, where contraction and increase of steric bulk of the ligand environment eventually excludes ternary complex formation.²⁵ The level of theory used in these calculations has been previously shown to perform well under most tests.^{26,27} Additionally, RMSD comparison between the XRD and DFT optimized structure for [Sc(L⁰⁰³)] yields an RMSD of 0.1946 (Table S3†).

Finally, as the metal center acts as a chiral center, the formation of Δ - and Λ -configurational isomers can induce differential selectivity for the formation of the corresponding ternary complex; specifically, [ScF(L¹¹¹)] provided different relative BDE and bond length values for the Δ - and Λ -isomers of the plus (P)- and minus (M)-isomeric forms. The formation of metallo-atropisomers is observed upon chelation with the achiral H₂L¹¹¹ due to the resulting three-dimensional structure of the complex. Fig. 5 depicts the resulting four diastereomers (combination of Δ/Λ - and P/M-isomers). To define the P- and M-isomers, the tacn-based ligand is depicted as having three different pendant arms: X, Y and Z with priority determined by the rules dictating traditional carbon-based *R/S* isomers. In this case the acetate pendant arm is given highest priority (X), the amide is given Y, and the picolinate is depicted as Z. Then

following the pendant arms around the macrocycle X–Y–Z, a clockwise direction gives the P-isomer and counterclockwise gives the M-isomer. The complexity of the ¹H NMR spectra for [Sc(L¹¹¹)]⁺, ScF(L¹¹¹), and [Lu(L¹¹¹)]⁺ as well as the observation of multiple signals in their respective HPLC traces is likely a result of this high degree of isomerization (additional *E*- and *Z*-isomers of the amide functional group are also observed for all three complexes and the H₂L¹¹¹, see ESI, Fig. S25, S31 and S38†). Metallo-atropisomers are frequently observed with poly-functionalized azamacrocyclic chelates, however rapid interconversion of the respective isomers generally precludes isolation of the corresponding species.²⁸

Here, we hypothesize that interconversion between Δ - and Λ -isomers of Sc³⁺ complexes; given the calculated ± 8 kJ mol⁻¹ difference in energy observed using DFT between these isomers, a Sc³⁺-[L¹¹¹]²⁻ interaction energy of ~ -890 kJ mol⁻¹ is likely too large to overcome for interconversion of P- and M-isomers. Thus, we hypothesized the all four metal-based isomers of [Sc(L¹¹¹)]⁺, ScF(L¹¹¹), and [Lu(L¹¹¹)]⁺ would be observed using chiral separation approaches. Indeed, the corresponding characterization of [Sc(L¹¹¹)]⁺ using chiral chromatography resolved 4 individual species (with a ratio of 35:14:34:17) and providing identical mass spectrometric signature (ESI, Fig. S23, Table S4†).





Fig. 5 Description and depiction of 4 distinct metallo-atropisomers of [Sc(L¹¹¹)]⁺ and their interconversion enthalpies/isomerization equilibria. Structures are depicted schematically (center), and corresponding [Sc(L¹¹¹)]⁺ complexes (DFT-optimized) are shown adjacent to each isomer with isomeric descriptors. Specifically, M/P refers to directionality induced by the orientation of the arm substituents, whereas Δ - and Λ -refers to directionality of the arm substituents and the macrocycle induced by metal complexation.



Scheme 1 Reaction scheme and conditions for radiochemical labeling conversion screen with ¹⁸F, ⁴⁴Sc, ¹⁷⁷Lu isotopes.



Radiochemical labeling studies and formulation stability

In accordance with our goal to identify coordinative structures that could efficiently incorporate and coordinatively stabilize the radioisotopes ^{18}F , ^{44}Sc and ^{177}Lu , we conducted radiochemical labeling studies next. Following previously established radiochemical labelling approaches (Scheme 1),¹³ we radiofluorinated by pre-formation of the $^{18}\text{F}[\text{ScF}]^{2+}$ species which was subsequently mixed with the ligand at 100 nmol mCi^{-1} molar activity and incubated at 80 °C for 30 min at pH 4.8 (1 M NH_4Ac buffer). Radiochemical conversions were determined using iTLC or radioHPLC measurements (ESI, Fig. S24–S39†), and radiochemical purity and formulation stability affirmed using radioHPLC. Under these conditions the majority of ^{44}Sc and ^{177}Lu complexes form readily, with high radiochemical conversions and purity of 80% and above. The main discrepancies were observed among the two nuclides with respect their tolerance for amide donors and lower denticity ligand systems (Table 4). Lower ligand denticity and amide donation is generally better tolerated by Sc, which exhibits more covalent bonding character and smaller ionic radius, while Lu shows a preference for ligand systems with greater negative charge for charge equilibration of the trivalent metal cation. Large discrepancies in labeling efficiency were observed for ^{18}F : specifically, 6-coordinate systems produced lower radiochemical conversions ranging from 0 to 14%, with 7-coordinate systems affording significantly higher conversions of 19–37%. Indeed, radiochemical conversions correlated well with computational data, which predicts strengthening of the Sc–F and weakened Sc–OH₂ bond for $[\text{ScF}(\text{L}^{201})]^-$ and $[\text{ScF}(\text{L}^{111})]$ systems. Poor charge equilibration and increased steric bulk likely limits attainable radiochemical conversions for $[\text{ScF}(\text{L}^{021})]^+$. In accordance with our prediction that 8- and 9-coordinate ligand systems did not accommodate inner-sphere ternary ligands, no formation of the radiofluorinated product

was observed for the for $[\text{Sc}(\text{L}^{102})]$, $[\text{Sc}(\text{L}^{012})]^+$ and $[\text{Sc}(\text{L}^{003})]$ complexes. Complexes that could be efficiently separated using preparative HPLC and exhibited sufficient formulation stability upon reanalysis, were employed for subsequent *in vivo* experiments.

In vivo biodistribution and metabolite analysis

While *in vitro* stability studies can give some indication about the relative inertness of radiochelate complexes to plasma protein binding, transchelation and metal ion selectivity, *in vivo* biodistribution and urine metabolite analysis have proven the most reliable predictors of *in vivo* performance in our hands. Importantly, biodistribution profiles must be compared to those of the corresponding non-chelated isotopes to determine off-target deposition due to de- or transchelation. To this end, Sc^{18}F and ^{44}Sc complexes were synthesized, radiochromatographically separated, and reformulated in phosphate buffered saline (PBS) prior for injection. Formulated complexes were injected intravenously into cohorts of balb/C naïve mice, ex vivo biodistribution and urine metabolite analysis was conducted 1 hour post injection, taking into consideration the short circulation time of small molecular complexes. Detailed biodistribution analysis of all organs can be found within the ESI (Tables S4–S9†). A graphical summary of a key set of organs (blood, liver, spleen, bone) is shown graphically in Fig. 6, together with comparative data sets of the corresponding free ion distributions of Sc^{3+} and F^- . Our control data sets show pronounced blood, liver and splenic uptake as typical hallmarks of Sc^{3+} release, while elevated bone uptake is characteristic of labile F^- . Among the tested chelate systems, the 6-coordinate donor environment resulted in biodistribution profiles indicative of dechelation, while 7-coordinate system exhibited improved inertness, with low deposition of radioactivity across all relevant off-target organs. Of note, attempts to reformulate $^{18}\text{F}[\text{ScF}(\text{L}^{021})]^+$ in PBS following chromatographic separation were not successful, indicating diminished complex inertness. Based on the biodistribution screen, H_3L^{201} and H_2L^{111} remained of interest for further investigation. Subsequently, we formed the corresponding $^{177}\text{Lu}[\text{Lu}(\text{L}^{201})]$ and $^{177}\text{Lu}[\text{Lu}(\text{L}^{111})]^+$ complexes and conducted matching biodistribution analysis. Results indicate good correlation of ^{18}F , ^{44}Sc and ^{177}Lu profiles (Fig. 7), evident for most organs except the kidneys, which is elevated for both ^{177}Lu complexes. The reason for this behavior is unclear, considering the corresponding ^{44}Sc complex exhibits identical chemical properties. Elevated liver and intestinal uptake for the H_2L^{111} series are a consequence of the increased lipophilicity compared to the H_3L^{201} series, as the metabolite analysis does not exhibit significantly diminished inertness of the rare earth complexes when compared across compound series. Of note, the two neutral complexes $^{177}\text{Lu}[\text{Lu}(\text{L}^{201})]$ and $^{18}\text{F}[\text{ScF}(\text{L}^{111})]$ exhibit highest inertness in isolated urine metabolites, indicating that interaction of cationic or anionic complexes with blood serum proteins may induce accelerated destabilization. For both complex series, inertness remained favorable and biodistribution profiles indicated no significant off target

Table 4 Radiochemical labeling conversions at 100 nmol mCi^{-1} molar activity, 80 °C, 30 min at pH 4.8. Color coding indicates relative radiochemical conversion ranging from red (low relative conversion) to blue (high relative conversion). Columns are color coded independently from one another

Ligand	^{18}F	^{44}Sc	^{177}Lu	Ligand denticity
H_3L^{300}	0	98.6	81.3	6
$\text{H}_3\text{L}^{300-\text{BzNH}_2}$	2.1	74.4	99	6
L^{030}	0	81.4	8.8	6
H_2L^{210}	7.9	91.5	62	6
HL^{120}	14.1	96.7	94.8	6
H_3L^{201}	33.3	99.1	99.3	7
H_2L^{111}	36.7	97.5	90.2	7
HL^{021}	19	96	83	7
H_2L^{012}	0	92.5	98.9	8
H_3L^{102}	0	95.1	99	8
H_3L^{003}	0	95.6	97.5	9



1h Post Injection Biodistribution Analysis




Fig. 6 Summary of 1 h post injection biodistribution analysis of Sc^{18}F and 44Sc complexes in direct comparison with the distribution profile of corresponding free ion species in key organs blood, liver, spleen and bone indicate that 7-coordinate chelates result in improved complex inertness and a more favorable *in vivo* distribution profile.




Fig. 7 (A) Biodistribution analysis 1 hour post injection of $[\text{Sc}(\text{L}^{201})]$, $[\text{ScF}(\text{L}^{201})]^-$ and $[\text{Lu}(\text{L}^{201})]$. (B) Biodistribution analysis 1 hour post injection of $[\text{Sc}(\text{L}^{111})]^+$, $[\text{ScF}(\text{L}^{111})]$ and $[\text{Lu}(\text{L}^{111})]^+$. (C) Quantitation of intact metabolite in the urine for each investigated species as determined by radioHPLC analysis.

accumulation, motivating future investigation of conjugate systems to determine the chelators' suitability of targeted imaging and therapy applications.

pH-dependent speciation for lead chelates

To further compare and contrast the pH dependent speciation of Sc^{3+} and Lu^{3+} complexes with H_3L^{201} and H_2L^{111} , spectrophotometric and NMR-assisted speciation studies were performed. Specifically, ligand and complex samples were

prepared at 23 different pH values (2–12). Corresponding ^1H and UV-visible spectra were acquired and data was processed using multiparameter fitting with HypSpec and HypNMR programs to determine pH dependent complex speciation, and complex pK_a , $\log K_{\text{ML}}$ and pM values (Fig. 8, Tables S10–S11[†]). Our data indicates that the difference in ligand charge lowers the pK_a of formation of the $[\text{M}(\text{OH})(\text{L}^{111})]$ when compared with $[\text{MOH}(\text{L}^{201})]$. Fig. 9 compares the speciation of the H_2L^{111} complex series with the previously characterized H_3L^{201}




Fig. 8 Speciation plots of $[\text{Sc}(\text{L}^{111})]^+$ (top), $[\text{Lu}(\text{L}^{111})]^+$ (bottom left).






Fig. 9 Summary of pK_a values obtained for the $M(L^{111})$ series in direct comparison with the $M(L^{201})$ complexes, $M = Sc, Lu$.

complexes and identifies the following trends: formation of Sc complexes occurs at lower pH in both instances, whereas the formation of the $MOH(L^{xxx})$ species requires lower OH^- concentrations for Lu complexes. This correlates inversely with the reported ionic hardness values for the individual M^{3+} ions.²⁹

The acquired speciation data helps rationalize bio-distribution and stability study results: specifically, the speciation data indicates likely prevalence of $[M(OH)(L^{111})]$, and not the aqua ion $[MOH_2(L^{111})]^+$ (for $M = Sc, Lu$) under physiologically relevant conditions. For both metals, the OH^- complex is more prevalent at physiological pH when complexed with H_2L^{111} in comparison to H_3L^{201} . This contrasts with the $[M(L^{201})]$ complexes, where the hydroxide species remains negligible at physiological pH and indicates that OH^- complex species are biocompatible and can remain inert *in vivo*.

Conclusions

Here, we have employed a variety of characterization methods to explore the coordinative and chemical reactivity landscape of ten triaza-macrocyclic chelates in the context of the ^{18}F -Sc/ ^{44}Sc / ^{177}Lu triad. In this study density functional theory, convergent chemical synthesis, heteronuclear NMR spectroscopy, radiochemical screening, *in vivo* biodistribution, metabolite analysis, and pH-dependent speciation were utilized. In accordance with our hypothesis, 7-coordinate chelators are ideally suited to form F-Sc/Sc/Lu coordination complexes. Solution coordination number can be affirmed by ^{45}Sc NMR spectroscopy, with corresponding complexes exhibiting a characteristic chemical shift of 65–75 ppm in MeOH. Charge equilibration is paramount, to stabilize all three complex-types; as such, complexes outside of the -1 to $+1$ charge range were not sufficiently inert in solution. All complexes form Δ - and Λ -enantiomers, with H_2L^{111} forming additional M- and P- forms, producing 4 distinct isomers consisting of two diastereomeric pairs of Δ - and Λ -enantiomers. While radiochemical labelling was feasible (and in some instances high-yielding) with 6- and 7-coordinate chelators, 6-coordinative complexes exhibited limited *in vivo* stability as evidenced by enhanced blood

retention of the ^{44}Sc complexes and bone-deposition of ^{18}F . *In vivo* analysis identifies complexes of H_3L^{201} and H_2L^{111} as most ideally suited for the future construction of bifunctional derivatives; pH dependent speciation indicates that both ligands form neutral, charge-balanced $[M(L^{201})]$ and $[M(OH)(L^{111})]$ species respectively between pH 6–8. This work serves as a blueprint for the design of bifunctional chelators compatible with ^{18}F / ^{44}Sc / ^{177}Lu isotopes, providing clear spectroscopic, radiochemical labeling and biological performance benchmarks.

Data availability

Crystallographic data for $[Sc(L^{003})] \cdot 3H_2O$ been deposited at the CCDC under 2369298. The datasets supporting this article have been uploaded as part of the ESI† specifically, we provide processed NMR spectroscopic information, chromatographic analysis spectra, UV-Vis spectra and tabulated biodistribution and stability analysis data as an average of single cohorts of animals as indicated. Additional, raw data is available upon request to the corresponding author.

Author contributions

CAAK, OMG and EB designed all experimental approaches and wrote the manuscript. CAAK, OMG, JNW conducted radiochemical labeling and animal experimentation. KMS and IAG conducted crystallographic data acquisition and analysis. TEB, EAS, JCM, JWE conducted isotope production and separation.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Dr Heike Hofstetter is acknowledged for her support in establishing various heteronuclear NMR pulse programs and acquisition methods. E. B. and J. W. E. acknowledge the National Institutes of Bioimaging and Bioengineering (R01EB032349) and the Department of Energy (0000262368) for funding support of this work. The following instrumentation in the Paul Bender Chemical Instrumentation Center at the University of Wisconsin-Madison was supported by: NSF CHE-2017891 (Bruker Avance Neo 500); by a generous gift from Paul J. and Margaret M. Bender (Bruker Quazar APEX2 and Bruker 500); NIH S10 OD012245 (Bruker Avance-600). The Bruker D8 VENTURE Photon III X-ray diffractometer was partially funded by NSF Award #CHE-1919350 to the UW-Madison Department of Chemistry and the Electrospray Ionization-Quadrupole-Ion Trap Mass Spectrometer was funded by NIH 1S10 OD020022.

References

- 1 A. C. Civelek, Reawakening of Nuclear Medicine through Molecular Imaging: Quantitative Theranostics and PSMA PET, *Radiology*, 2023, **307**, e230627.



- 2 N. Drude, L. Tienken and F. M. Mottaghy, Theranostic and nanotheranostic probes in nuclear medicine, *Methods*, 2017, **130**, 14–22.
- 3 X. Deng, J. Rong, L. Wang, N. Vasdev, L. Zhang, L. Josephson and S. H. Liang, Chemistry for positron emission tomography: recent advances in ^{11}C -, ^{18}F -, ^{13}N -, and ^{15}O -labeling reactions, *Angew. Chem., Int. Ed.*, 2019, **58**, 2580–2605.
- 4 S. Richter, M. Wuest, C. N. Bergman, J. D. Way, S. Krieger, B. E. Rogers and F. Wuest, Rerouting the metabolic pathway of ^{18}F -labeled peptides: the influence of prosthetic groups, *Bioconjugate Chem.*, 2015, **26**, 201–212.
- 5 V. Bernard-Gauthier, J. J. Bailey, Z. Liu, B. r. Wängler, C. Wängler, K. Jurkschat, D. M. Perrin and R. Schirrmacher, From unorthodox to established: The current status of ^{18}F -trifluoroborate- and ^{18}F -SiFA-based radiopharmaceuticals in PET nuclear imaging, *Bioconjugate Chem.*, 2016, **27**, 267–279.
- 6 M. L. Lepage, H. T. Kuo, Á. Roxin, S. Huh, Z. Zhang, R. Kandasamy, H. Merckens, J. O. Kumlin, A. Limoges, S. K. Zeisler, K. S. Lin, F. Bénard and D. M. Perrin, Toward ^{18}F -Labeled Theranostics: A Single Agent that Can Be Labeled with ^{18}F , ^{64}Cu , or ^{177}Lu , *ChemBioChem*, 2019, **20**, e201900632.
- 7 W. J. McBride, R. M. Sharkey and D. M. Goldenberg, Radiofluorination using aluminum-fluoride (Al^{18}F), *EJNMMI Res.*, 2013, **3**, 1–11.
- 8 C. Fersing, A. Bouhlel, C. Cantelli, P. Garrigue, V. Lisowski and B. Guillet, A comprehensive review of non-covalent radiofluorination approaches using aluminum [^{18}F] fluoride: Will [^{18}F] ALF replace ^{68}Ga for metal chelate labeling?, *Molecules*, 2019, **24**, 2866.
- 9 E. W. Price and C. Orvig, Matching chelators to radiometals for radiopharmaceuticals, *Chem. Soc. Rev.*, 2014, **43**, 260–290.
- 10 N. P. van der Meulen, M. Bunka, K. A. Domnanich, C. Muller, S. Haller, C. Vermeulen, A. Turler and R. Schibli, Cyclotron production of ^{44}Sc : From bench to bedside, *Nucl. Med. Biol.*, 2015, **42**, 745–751.
- 11 C. Muller, M. Bunka, S. Haller, U. Koester, V. Groehn, P. Bernhardt, N. van der Meulen, A. Tuerler and R. Schibli, Promising prospects for ^{44}Sc - ^{47}Sc -based theragnostics: application of ^{47}Sc for radionuclide tumor therapy in mice, *J. Nucl. Med.*, 2014, **55**, 1658–1664.
- 12 K. A. Domnanich, C. Müller, M. Benešová, R. Dressler, S. Haller, U. Köster, B. Ponsard, R. Schibli, A. Türler and N. P. van der Meulen, ^{47}Sc as useful β -emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes, *EJNMMI Radiopharm. Chem.*, 2017, **2**, 5.
- 13 J. N. Whetter, B. A. Vaughn, A. J. Koller and E. Boros, An Unusual Pair: Facile Formation and In Vivo Validation of Robust $\text{Sc-}^{18}\text{F}$ Ternary Complexes for Molecular Imaging, *Angew. Chem., Int. Ed.*, 2022, **61**, e202114203.
- 14 G. Nagy, D. Szikra, G. Trencsényi, A. Fekete, I. Garai, A. M. Giani, R. Negri, N. Masciocchi, A. Maiocchi, F. Uggeri, I. Tóth, S. Aime, G. Giovenzana and Z. Baranyai, AAZTA: an ideal chelating agent for the development of ^{44}Sc PET imaging agents, *Angew. Chem., Int. Ed.*, 2017, **56**, 2118–2122.
- 15 C. Gateau, M. Mazzanti, J. Pécaut, F. A. Dunand and L. Helm, Solid-state and solution properties of the lanthanide complexes of a new nonadentate tripodal ligand derived from 1, 4, 7-triazacyclononane, *Dalton Trans.*, 2003, 2428–2433.
- 16 G. N. Nocton, A. Nonat, G. Christelle and M. Marinella, Water Stability and Luminescence of Lanthanide Complexes of Tripodal Ligands Derived from 1,4,7-Triazacyclononane: Pyridinecarboxamide versus Pyridinecarboxylate Donors, *Helv. Chim. Acta*, 2009, **92**, 2257–2273.
- 17 K. Mason, A. C. Harnden, C. W. Patrick, A. W. J. Poh, A. S. Batsanov, E. A. Suturina, M. Vonci, E. J. L. McInnes, N. F. Chilton and D. Parker, Exquisite sensitivity of the ligand field to solvation and donor polarisability in coordinatively saturated lanthanide complexes, *Chem. Commun.*, 2018, **54**, 8486–8489.
- 18 R. Bhalla, W. Levason, S. K. Luthra, G. McRobbie, G. Sanderson and G. Reid, Radiofluorination of a pre-formed gallium (III) aza-macrocyclic complex: towards next-generation positron emission tomography (PET) imaging agents, *Chem.–Eur. J.*, 2015, **21**, 4688.
- 19 N. Kim, C.-H. Hsieh and J. F. Stebbins, Scandium Coordination in Solid Oxides and Stabilized Zirconia: ^{45}Sc NMR, *Chem. Mater.*, 2006, **18**, 3855–3859.
- 20 A. J. Rossini and R. W. Schurko, Experimental and Theoretical Studies of ^{45}Sc NMR Interactions in Solids, *J. Am. Chem. Soc.*, 2006, **128**, 10391–10402.
- 21 A. Jaworski, T. Charpentier, B. Stevansson and M. Edén, Scandium and Yttrium Environments in Aluminosilicate Glasses Unveiled by $^{45}\text{Sc}/^{89}\text{Y}$ NMR Spectroscopy and DFT Calculations: What Structural Factors Dictate the Chemical Shifts?, *J. Phys. Chem. C*, 2017, **121**, 18815–18829.
- 22 E. Curnock, W. Levason, M. E. Light, S. K. Luthra, G. McRobbie, F. M. Monzittu, G. Reid and R. N. Williams, Group 3 metal trihalide complexes with neutral N-donor ligands – exploring their affinity towards fluoride, *Dalton Trans.*, 2018, **47**, 6059–6068.
- 23 A. Hu, M. E. Simms, V. Kertesz, J. J. Wilson and N. A. Thiele, Chelating rare-earth metals (Ln^{3+}) and $^{225}\text{Ac}^{3+}$ with the dual-size-selective macrocyclic ligand Py2-macrodipa, *Inorg. Chem.*, 2022, **61**, 12847–12855.
- 24 A. Hu, V. Brown, S. N. MacMillan, V. Radchenko, H. Yang, L. Wharton, C. F. Ramogida and J. J. Wilson, Chelating the alpha therapy radionuclides $^{225}\text{Ac}^{3+}$ and $^{213}\text{Bi}^{3+}$ with 18-membered macrocyclic ligands macrodipa and Py-macrodipa, *Inorg. Chem.*, 2021, **61**, 801–806.
- 25 S. Aime, M. Botta, M. Fasano, M. P. M. Marques, C. F. Geraldes, D. Pubanz and A. E. Merbach, Conformational and coordination equilibria on DOTA complexes of lanthanide metal ions in aqueous solution studied by ^1H -NMR spectroscopy, *Inorg. Chem.*, 1997, **36**, 2059–2068.



- 26 S. F. Yuk, I. Sargin, N. Meyer, J. T. Krogel, S. P. Beckman and V. R. Cooper, Putting error bars on density functional theory, *Sci. Rep.*, 2024, **14**, 20219.
- 27 N. Mardirossian and M. Head-Gordon, Thirty years of density functional theory in computational chemistry: an overview and extensive assessment of 200 density functionals, *Mol. Phys.*, 2017, **115**, 2315–2372.
- 28 A. Marlin, A. Koller, E. Madarasi, M. Cordier, D. Esteban-Gómez, C. Platas-Iglesias, G. Tircsó, E. Boros, V. Patinec and R. Tripier, H3 nota Derivatives Possessing Picolyl and Picolinate Pendants for Ga³⁺ Coordination and ⁶⁷Ga³⁺ Radiolabeling, *Inorg. Chem.*, 2023, **62**, 20634–20645.
- 29 R. G. Parr and R. G. Pearson, Absolute hardness: companion parameter to absolute electronegativity, *J. Am. Chem. Soc.*, 1983, **105**, 7512–7516.

